EL7.AI
StocksMedium•18 November 2026•
1 min read

Brazil's Anvisa Approves Johnson & Johnson's ICOTYDE for Plaque Psoriasis

Key Facts

1The Brazilian Health Regulatory Agency (Anvisa) approved Johnson & Johnson's icotroquinra for the treatment of plaque psoriasis.

The Brazilian Health Regulatory Agency (Anvisa) approved Johnson & Johnson's icotroquinra, marketed as ICOTYDE, for the treatment of plaque psoriasis. Benzinga reported that the approval covers the use of the oral peptide for moderate-to-severe cases in both adults and adolescents.

Johnson & Johnson stock, trading under the ticker JNJ, closed at $272.69 on November 18, 2026, after reaching a session high of $278.7029. The regulatory milestone expands the company's immunology portfolio in Brazil by providing a new oral treatment option for patients.

Open on chart